53 results
Page 2 of 3
8-K
EX-99.1
zoc9r55qoxdr7xz
11 Feb 22
Passage Bio Presents New Interim Clinical Data for Patients with GM1 Gangliosidosis in Imagine-1 Study at 2022 WORLDSymposium
11:00am
8-K
EX-99.2
3px2kqsf 416egu
11 Feb 22
Passage Bio Presents New Interim Clinical Data for Patients with GM1 Gangliosidosis in Imagine-1 Study at 2022 WORLDSymposium
11:00am
8-K
EX-99.2
gxl109dvh5nyuug57m
10 Jan 22
Passage Bio Announces 2022 Research and Clinical Development Goals to Advance Robust CNS Pipeline
8:00am
8-K
EX-99.2
7i5bio rj
17 Dec 21
Passage Bio Announces Positive Interim Safety and Biomarker Data and Advances Phase 1/2 Trial of PBGM01 in GM1 Gangliosidosis
7:01am
8-K
EX-99.2
3j8efiy 87tgr
4 Nov 21
Passage Bio Reports Third Quarter 2021 Financial Results and Provides Recent Business Highlights
8:00am
8-K
EX-99.1
xjwspsioeh2
4 Oct 21
Regulation FD Disclosure
7:31am
8-K
EX-99.2
jv0q5dei3iyr83zsp93
5 Aug 21
Passage Bio Reports Second Quarter 2021 Financial Results and Provides Recent Business Highlights
7:01am
8-K
EX-99.2
ky7cv
5 May 21
Passage Bio Reports First Quarter 2021 Financial Results and Recent Business Highlights
7:00am
S-3ASR
EX-4.3
04z4tt fv78ab
5 Mar 21
Automatic shelf registration
5:22pm
10-K
tldgkqik2qm 39v7o
3 Mar 21
Annual report
8:01am
8-K
EX-99.2
ccjauwx8btdy
3 Mar 21
Passage Bio Reports Fourth Quarter and Full-Year 2020 Financial Results and Recent Business Highlights
7:01am
8-K
zs0uk
17 Feb 21
Departure of Directors or Certain Officers
5:00pm
424B1
r0h0n6opkj6aytlgodx2
22 Jan 21
Prospectus with pricing info
4:31pm
8-K
EX-99.2
j8na cm35vwt
11 Jan 21
Passage Bio Announces Plan to Deliver on Multiple Meaningful Catalysts in 2021
7:15am
8-K
EX-10.1
kkexqd709
18 Dec 20
Entry into a Material Definitive Agreement
7:00am
DRS
mf38h3i3rplw0q6bjls4
18 Dec 20
Draft registration statement
12:00am